Nuclear receptors: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
Line 9: | Line 9: | ||
F: C-terminal domain | F: C-terminal domain | ||
='''Thyroid Hormone Receptor-like'''= | |||
==[[Peroxisome Proliferator-Activated Receptors]]== | |||
= '''Estrogen Receptor-like'''= | = '''Estrogen Receptor-like'''= | ||
== [[Estrogen receptor]]== | == [[Estrogen receptor]]== | ||
Line 14: | Line 16: | ||
== 3-Ketosteroid receptors== | == 3-Ketosteroid receptors== | ||
===[[Androgen receptor]]=== | ===[[Androgen receptor]]=== | ||
=[[Glucocorticoid receptor]]= | =[[Glucocorticoid receptor]]= | ||
=[[Vitamin D receptor]]= | =[[Vitamin D receptor]]= |
Revision as of 20:03, 25 January 2021
Under development!!! Nuclear receptor structure is composed of 5 domains - A/B: N-terminal regulatory domain contains activation function 1 (residues 101-370), activation function 5 (residues 360-485) and dimerization surface (residues 1-36 and 370-494). Thyroid Hormone Receptor-likePeroxisome Proliferator-Activated ReceptorsEstrogen Receptor-likeEstrogen receptor3-Ketosteroid receptorsAndrogen receptorGlucocorticoid receptorVitamin D receptor |
|
ReferencesReferences
- ↑ Bohl CE, Wu Z, Chen J, Mohler ML, Yang J, Hwang DJ, Mustafa S, Miller DD, Bell CE, Dalton JT. Effect of B-ring substitution pattern on binding mode of propionamide selective androgen receptor modulators. Bioorg Med Chem Lett. 2008 Oct 15;18(20):5567-70. Epub 2008 Sep 5. PMID:18805694 doi:10.1016/j.bmcl.2008.09.002